Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MLYCD | O95822 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 3/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.30 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL256775 | 0.83 | MLYCD (0.41) | MLYCDMEN1KMT2AHTTHPGD | |
| SCHEMBL21361324 | 0.80 | MLYCD (0.43) | MLYCDMEN1KMT2AHTTHPGD | |
| SCHEMBL17894222 | 0.79 | MLYCD (0.42) | MLYCDMEN1KMT2AHTTHPGD | |
| SCHEMBL25257215 | 0.77 | MLYCD (0.36) | MLYCDMEN1KMT2AHTTHPGD | |
| SCHEMBL25256351 | 0.75 | MLYCD (0.38) | MLYCDMEN1KMT2AHTTHPGD | |
| SCHEMBL30602390 | 0.72 | ALDH1A1 (0.42) | MEN1KMT2AHTTHPGDALDH1A1 | |
| SCHEMBL2272338 | 0.71 | MLYCD (0.45) | MLYCDMEN1KMT2AHTTHPGD | |
| SCHEMBL25652557 | 0.70 | MLYCD (0.44) | MLYCDMEN1KMT2AHTTHPGD | |
| SCHEMBL589423 | 0.70 | MLYCD (0.48) | MLYCDMEN1KMT2AHTTHPGD | |
| SCHEMBL3706341 | 0.70 | MEN1 (0.58) | MLYCDMEN1KMT2AHTTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12018011-B2 | Macrocyclic compounds and compositions, and methods of preparing and using the same | KURA ONCOLOGY, INC. (US) | 2024-06-25 | — | — | US | disclosed |
| US-20230322711-A1 | MACROCYCLIC COMPOUNDS AND COMPOSITIONS, AND METHODS OF PREPARING AND USING THE SAME | WUXI APPTEC (HONG KONG) LIMITED (CN) | 2023-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12018011-B2 | Macrocyclic compounds and compositions, and methods of preparing and using the same | FNTA, FDPS, GGPS1 | MLYCD 1364/4885MEN1 72/4885KMT2A 4281/4885 |
| US-20230322711-A1 | MACROCYCLIC COMPOUNDS AND COMPOSITIONS, AND METHODS OF PREPARING AND USING THE SAME | FNTA, FDPS, GGPS1 | MLYCD 1364/4885MEN1 72/4885KMT2A 4281/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.